Clinical study of Yiqi Liangxue Shengji prescription for improving cardiac function after myocardial ischemia reperfusion injury in patients with acute myocardial infarction: a randomized, double-blind, placebo-controlled trial.
This study demonstrated that the addition of YQLXSJ to standard therapy can improve cardiac function and alleviate clinical symptoms in AMI patients with MIRI, and also showed a potential to mitigate the incidence of MACE. Furthermore, YQLXSJ displayed a favorable safety profile in clinical application.
Authors
- Wang Wujiao
- Liyang Dong
- Kun Zhou (ORCID: https://orcid.org/0000-0002-4058-7497)
- LV Yu-xuan
- Jing Liu (ORCID: https://orcid.org/0000-0002-3311-0818)
- Li-Shan Yan (ORCID: https://orcid.org/0000-0002-1124-4241)
- Qian Lin (ORCID: https://orcid.org/0000-0001-8980-2269)
- Xiaoyun Cui (ORCID: https://orcid.org/0000-0002-1478-4657)
- Jie Wan (ORCID: https://orcid.org/0000-0003-4430-4324)
- Lu Jinjin
Institutions
- Beijing University of Chinese Medicine (CN)
- Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-08-01
- DOI
- https://doi.org/10.19852/j.cnki.jtcm.2025.04.012
- Citations
- 1
- Primary Topic
- Traditional Chinese Medicine Analysis
- Type
- article
- Field-Weighted Citation Impact
- 2.38